Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN · IEX Real-Time Price · USD
0.850
-0.046 (-5.11%)
At close: Apr 12, 2024, 3:57 PM
0.851
+0.001 (0.12%)
After-hours: Apr 12, 2024, 5:31 PM EDT
-5.11%
Market Cap 5.84M
Revenue (ttm) n/a
Net Income (ttm) -12.40M
Shares Out 6.87M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,874
Open 0.900
Previous Close 0.896
Day's Range 0.849 - 0.900
52-Week Range 0.740 - 11.910
Beta 0.02
Analysts Strong Buy
Price Target 22.50 (+2,547.06%)
Earnings Date Mar 25, 2024

About ALZN

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ALZN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ALZN stock is "Strong Buy" and the 12-month stock price forecast is $22.5.

Price Target
$22.5
(2,547.06% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.

5 months ago - Business Wire

Alzamend Neuro Announces Reverse Stock Split

ATLANTA--(BUSINESS WIRE)---- $ALZN #15_to_1_stock_reversal--Alzamend Neuro Announces Reverse Stock Split.

5 months ago - Business Wire

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer's disease (Alzheimer's...

1 year ago - Business Wire

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--Ault Alliance Announces Alzamend Neuro Initiated Its Phase I/IIA Trial for Immunotherapy Vaccine ALZN002 to Treat Mild to Moderate Alzheimer's Disease

1 year ago - Business Wire

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

LAS VEGAS--(BUSINESS WIRE)--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), today announced that the Company is considering undertaking an e...

1 year ago - Business Wire

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

NEW YORK, NY / ACCESSWIRE / November 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently iss...

1 year ago - Accesswire

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

LAS VEGAS--(BUSINESS WIRE)--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), reported its financial results for the third quarter ended Septe...

1 year ago - Business Wire

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) today announced that Alzamend Neuro, Inc. (Nasdaq: ...

1 year ago - Business Wire

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

1 year ago - Business Wire

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determin...

2 years ago - Benzinga

See Why Alzamend Neuro Stock Is Rallying On Thursday

Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path...

2 years ago - Benzinga

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Inc (NASDAQ: ALZN) is surging higher Thursday after the company announced it received a written response to its meeting request relating to its Type B Pre‑IND application from the FDA p...

2 years ago - Benzinga

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #2nd_Treatment_to_Clinic--Alzamend Neuro Gets Positive FDA Pre-IND Response for AL002, a Therapeutic Vaccine that Seeks to Restore Patient's Immuno System to Com...

2 years ago - Business Wire

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Initiates Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease; Doses First Participant Group

2 years ago - Business Wire

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Additional $2M Investment from Digital Power Lending Due to Its IND Application for AL001 for Dementia Related to Alzheimers

2 years ago - Business Wire

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits Pre-IND for AL002 as Therapeutic Vaccine That Seeks to Restore Ability of Patient's Immunological System to Combat Alzheimer's

2 years ago - Business Wire

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives FDA “Study May Proceed” Letter for AL001 Phase 1 Clinical Study Investigational New Drug Application for Alzheimer's Disease

2 years ago - Business Wire

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Inc (NASDAQ: ALZN) has announced positive toxicology results for AL002 in a toxicology study using a transgenic mouse model of Alzheimer's disease.  Charles River Laboratories conducted...

2 years ago - Benzinga

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Positive Results for AL002, a Mutant-Peptide Vaccine, in GLP CRL Tox Study Using Alzheimer's Disease Transgenic Mouse Model

2 years ago - Business Wire

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

TAMPA, Fla.--(BUSINESS WIRE)---- $ALZN #505b2--Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today at 9:15am ET; Alzamend Celebrates Successful Initial Public Offering and Corporate Milestone

2 years ago - Business Wire

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Ault Global Holdings Inc (NYSE: DPW), a diversified holding company, has announced that Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug application to the FDA for a Phase 1...

3 years ago - Benzinga

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits IND Application to the FDA for AL001, a lithium-based ionic cocrystal oral therapy for Dementia Related to Alzheimer's Disease

3 years ago - Business Wire

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Closing of Initial Public Offering & Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

3 years ago - Business Wire

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

LAS VEGAS--(BUSINESS WIRE)---- $AGH #AP--Ault Global Holdings Announces Alzamend Neuro (Nasdaq: ALZN) Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock at $5.00 per Share

3 years ago - Business Wire

Alzamend Neuro Announces Pricing of Initial Public Offering

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Pricing of Initial Public Offering of 2,500,000 Shares of its Common Stock at a Price to the Public of $5.00 per Share

3 years ago - Business Wire